AVI BioPharma to Present Company Overview at the UBS Global Life Sciences Conference
September 14 2011 - 8:00AM
Marketwired
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, announced today that the Company is scheduled to
present at the UBS Global Life Sciences Conference in New York, NY,
on Wednesday, September 21, at 3:00 p.m. Eastern Time. Chris
Garabedian, AVI's President and CEO, will provide a company
overview.
The presentation will be webcast live under the events section
of AVI's website at www.avibio.com and will be archived there
following the presentation for 90 days. Please connect to AVI's
website several minutes prior to the start of the broadcast to
ensure adequate time for any software download that may be
necessary.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of
novel RNA-based therapeutics for rare and infectious diseases, as
well as other select disease targets. Applying pioneering
technologies developed and optimized by AVI, the Company is able to
target a broad range of diseases and disorders through distinct
RNA-based mechanisms of action. Unlike other RNA-based approaches,
AVI's technologies can be used to directly target both messenger
RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either
down-regulate (inhibit) or up-regulate (promote) the expression of
targeted genes or proteins. By leveraging its highly differentiated
RNA-based technology platform, AVI has built a pipeline of
potentially transformative therapeutic agents, including
eteplirsen, which is in clinical development for the treatment of
Duchenne muscular dystrophy, and multiple drug candidates that are
in clinical development for the treatment of infectious disease.
For more information, please visit www.avibio.com.
AVI Media and Investor Contact: Erin Cox Manager, Corporate
Communications and Investor Relations 425.354.5140 Email Contact
AVI Media Contact: David Schull Russo Partners 212.845.4271 Email
Contact
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jul 2024 to Aug 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Aug 2023 to Aug 2024